Cargando…
Emerging Perspectives on Leukemia Inhibitory Factor and its Receptor in Cancer
Tumorigenesis and metastasis have deep connections to inflammation and inflammatory cytokines, but the mechanisms underlying these relationships are poorly understood. Leukemia Inhibitory Factor (LIF) and its receptor (LIFR), part of the interleukin-6 (IL-6) cytokine family, make up one such ill-def...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358831/ https://www.ncbi.nlm.nih.gov/pubmed/34395259 http://dx.doi.org/10.3389/fonc.2021.693724 |
_version_ | 1783737419779014656 |
---|---|
author | Christianson, Joe Oxford, Julia Thom Jorcyk, Cheryl L. |
author_facet | Christianson, Joe Oxford, Julia Thom Jorcyk, Cheryl L. |
author_sort | Christianson, Joe |
collection | PubMed |
description | Tumorigenesis and metastasis have deep connections to inflammation and inflammatory cytokines, but the mechanisms underlying these relationships are poorly understood. Leukemia Inhibitory Factor (LIF) and its receptor (LIFR), part of the interleukin-6 (IL-6) cytokine family, make up one such ill-defined piece of the puzzle connecting inflammation to cancer. Although other members of the IL-6 family have been shown to be involved in the metastasis of multiple types of cancer, the role of LIF and LIFR has been challenging to determine. Described by others in the past as enigmatic and paradoxical, LIF and LIFR are expressed in a diverse array of cells in the body, and the narrative surrounding them in cancer-related processes has been vague, and at times even contradictory. Despite this, recent insights into their functional roles in cancer have highlighted interesting patterns that may allude to a broader understanding of LIF and LIFR within tumor growth and metastasis. This review will discuss in depth the signaling pathways activated by LIF and LIFR specifically in the context of cancer–the purpose being to summarize recent literature concerning the downstream effects of LIF/LIFR signaling in a variety of cancer-related circumstances in an effort to begin teasing out the intricate web of contradictions that have made this pair so challenging to define. |
format | Online Article Text |
id | pubmed-8358831 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83588312021-08-13 Emerging Perspectives on Leukemia Inhibitory Factor and its Receptor in Cancer Christianson, Joe Oxford, Julia Thom Jorcyk, Cheryl L. Front Oncol Oncology Tumorigenesis and metastasis have deep connections to inflammation and inflammatory cytokines, but the mechanisms underlying these relationships are poorly understood. Leukemia Inhibitory Factor (LIF) and its receptor (LIFR), part of the interleukin-6 (IL-6) cytokine family, make up one such ill-defined piece of the puzzle connecting inflammation to cancer. Although other members of the IL-6 family have been shown to be involved in the metastasis of multiple types of cancer, the role of LIF and LIFR has been challenging to determine. Described by others in the past as enigmatic and paradoxical, LIF and LIFR are expressed in a diverse array of cells in the body, and the narrative surrounding them in cancer-related processes has been vague, and at times even contradictory. Despite this, recent insights into their functional roles in cancer have highlighted interesting patterns that may allude to a broader understanding of LIF and LIFR within tumor growth and metastasis. This review will discuss in depth the signaling pathways activated by LIF and LIFR specifically in the context of cancer–the purpose being to summarize recent literature concerning the downstream effects of LIF/LIFR signaling in a variety of cancer-related circumstances in an effort to begin teasing out the intricate web of contradictions that have made this pair so challenging to define. Frontiers Media S.A. 2021-07-29 /pmc/articles/PMC8358831/ /pubmed/34395259 http://dx.doi.org/10.3389/fonc.2021.693724 Text en Copyright © 2021 Christianson, Oxford and Jorcyk https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Christianson, Joe Oxford, Julia Thom Jorcyk, Cheryl L. Emerging Perspectives on Leukemia Inhibitory Factor and its Receptor in Cancer |
title | Emerging Perspectives on Leukemia Inhibitory Factor and its Receptor in Cancer |
title_full | Emerging Perspectives on Leukemia Inhibitory Factor and its Receptor in Cancer |
title_fullStr | Emerging Perspectives on Leukemia Inhibitory Factor and its Receptor in Cancer |
title_full_unstemmed | Emerging Perspectives on Leukemia Inhibitory Factor and its Receptor in Cancer |
title_short | Emerging Perspectives on Leukemia Inhibitory Factor and its Receptor in Cancer |
title_sort | emerging perspectives on leukemia inhibitory factor and its receptor in cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358831/ https://www.ncbi.nlm.nih.gov/pubmed/34395259 http://dx.doi.org/10.3389/fonc.2021.693724 |
work_keys_str_mv | AT christiansonjoe emergingperspectivesonleukemiainhibitoryfactoranditsreceptorincancer AT oxfordjuliathom emergingperspectivesonleukemiainhibitoryfactoranditsreceptorincancer AT jorcykcheryll emergingperspectivesonleukemiainhibitoryfactoranditsreceptorincancer |